Skye Bioscience to Present at the H.C. Wainwright Ophthalmology Conference
August 11, 2021 08:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat...
Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies
August 10, 2021 08:30 ET
|
Skye Bioscience, Inc.
THCVHS shows no signs of chromosomal or gene mutations in preclinical studies SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical...
Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors
July 26, 2021 08:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Expands Clinical Advisory Board with the Appointment of Ophthalmology Expert Dr. Miguel González-Andrades
June 10, 2021 08:30 ET
|
Skye Bioscience, Inc.
SAN DIEGO, CA, June 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Combination and Single Agent, in Preclinical Study
May 17, 2021 08:42 ET
|
Skye Bioscience, Inc.
THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of 32.4% and maintains an average IOP reduction of 26.5% at 9 hours,...
Skye Bioscience Completes CMC and GLP Production for THCVHS Lead Program
April 22, 2021 08:30 ET
|
Skye Bioscience, Inc.
Novel glaucoma drug ready for next development phase - GLP toxicology study – on critical path to first human clinical trialOngoing development of THCVHS includes near-term preclinical comparison with...
Skye Bioscience to Present at Upcoming Investment Conferences in April
April 15, 2021 08:45 ET
|
Skye Bioscience, Inc.
San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience to Present at Benzinga Biotech Small Cap Conference
March 18, 2021 08:45 ET
|
Skye Bioscience, Inc.
San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment
March 16, 2021 08:30 ET
|
Skye Bioscience, Inc.
San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board
March 08, 2021 08:39 ET
|
Skye Bioscience, Inc.
San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...